NMRA-511 / Neumora Therap - LARVOL DELTA

Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease (clinicaltrials.gov) - P1 | N=96 | Completed | Sponsor: Neumora Therapeutics, Inc. | Recruiting ➔ Completed

Trial completion • Alzheimer's Disease • CNS Disorders • Dementia

NMRA-511: On Track to Report Data from Phase 1b Signal-seeking Study in Alzheimer’s Disease (AD) Agitation Around the End of 2025 (GlobeNewswire) - "Neumora is on track to report data from a Phase 1b signal-seeking study evaluating NMRA-511 as a treatment for AD agitation around the end of 2025."

P1 data • Alzheimer's Disease

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) - "NMRA-511: On Track to Report Data from Phase 1b Study in Alzheimer’s Disease (AD) Agitation Around the End of 2025: Neumora is advancing a Phase 1b signal-seeking study evaluating NMRA-511 initially in healthy elderly adult participants in Part A and then people with agitation associated with dementia due to AD in Part B. The Company is on track to report data around the end of 2025."

P1 data • Trial status • Alzheimer's Disease

Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) - "Expect to progress next M4 positive allosteric modulator (PAM) program into the clinic by mid-2025...NMRA-511: On Track to Report Data from Phase 1b Study in Alzheimer’s Disease (AD) agitation by the end of 2025."

New trial • P1 data • Alzheimer's Disease

Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) - "Neumora is advancing a Phase 1b study in investigating NMRA-511 initially in healthy elderly adult participants and then people with agitation associated with dementia due to AD. The Company expects to report data from this study in the second half of 2025."

P1 data • Alzheimer's Disease • CNS Disorders

Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease (clinicaltrials.gov) - P1 | N=96 | Recruiting | Sponsor: Neumora Therapeutics, Inc.

New P1 trial • Alzheimer's Disease • CNS Disorders • Dementia

Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation (GlobeNewswire) - "Neumora Therapeutics, Inc...today announced the initiation of a Phase 1b study evaluating NMRA-511 for the treatment of agitation associated with dementia due to Alzheimer’s disease (AD)...The Phase 1b study will investigate NMRA-511 initially in healthy elderly adult participants and then people with agitation associated with dementia due to AD...The primary endpoint of this signal-seeking study is change from baseline to Week 8 on the Cohen-Mansfield Agitation Inventory total score. Neumora expects to report topline data from this Phase 1b study in the second half of 2025."

New P1 trial • P1 data • Alzheimer's Disease • CNS Disorders

NMRA-511, a Novel Vasopressin 1a (V1a) Receptor Antagonist Reduces Threat Behaviors in Marmosets and Alters EEG Power Spectra Similarly in Marmosets and Humans (ACNP 2022) - "Oral administration of the V1a antagonist NMRA-511 produced anxiolytic-like activity without sedation in the marmoset threat test. The same dose of NMRA-511 (10 mg/kg) that reduced anxiety in the marmoset demonstrated increased relative power in the alpha and theta spectral bands with trends in the beta band in this species. Furthermore, using phEEG as a translatable biomarker, NMRA-511 was evaluated in a healthy control population and demonstrated similar changes in alpha and theta power and trends in the beta band as were observed in the marmoset."

CNS Disorders • Mood Disorders • Psychiatry